Efficacy and safety of anlotinib in combination with ¹³¹I therapy in the treatment of distant metastatic differentiated thyroid cancer: a single-arm, phase II study
Authors
Xueyao Liu (ORCID: https://orcid.org/0000-0001-9473-8097)
Qian Su (ORCID: https://orcid.org/0000-0003-4351-2631)
Jianjing Liu
Jie Ying Fu (ORCID: https://orcid.org/0000-0002-5489-2732)
Fang Yang (ORCID: https://orcid.org/0000-0001-6922-6348)
Zhao Yang (ORCID: https://orcid.org/0000-0002-5891-5815)
Yan Zhang (ORCID: https://orcid.org/0000-0002-4342-9742)
Zhen Yang (ORCID: https://orcid.org/0000-0001-8293-3581)
Dong Dai (ORCID: https://orcid.org/0000-0003-1278-5581)
Yan Li (ORCID: https://orcid.org/0000-0001-6021-1641)
Efficacy and safety of anlotinib in combination with ¹³¹I therapy in the treatment of distant metastatic differentiated thyroid cancer: a single-arm, phase II study
Xueyao Liu, Qian Su, Jianjing Liu, Jie Ying Fu et al.
Journal
Frontiers in Oncology
Topics
Thyroid Cancer Diagnosis and Treatment
article
Efficacy and safety of anlotinib in combination with ¹³¹I therapy in the treatment of distant metastatic differentiated thyroid cancer: a single-arm, phase II study
Xueyao Liu, Qian Su, Jianjing Liu, Jie Ying Fu, Fang Yang, Zhao Yang, Yan Zhang, Zhen Yang, Dong Dai, Yan Li, Lina Tong
article en
Abstract
No abstract available for this paper.
Publication Tag
Frontiers in OncologyVol. 15
Institutions
Tianjin Medical University Cancer Institute and Hospital (CN)